Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - valaciklovir - filmsko obložena tableta - valaciklovir 500 mg / 1 tableta - valaciklovir

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

arrow generics limited - valsartan - filmsko obložena tableta - valsartan 80 mg / 1 tableta - valsartan

Evropska unija - slovenščina - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastična sredstva - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinom, pljučni pljuč - antineoplastična sredstva - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - zdravila z delovanjem na novotvorbe agenti - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplazme dojke - endokrini terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, tenofovir alafenamide - okužbe z virusom hiv - antivirusi za sistemsko uporabo - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Evropska unija - slovenščina - EMA (European Medicines Agency)

gilead sciences ireland uc - tenofovir alafenamid fumarat - hepatitis b - antivirusi za sistemsko uporabo - vemlidy is indicated for the treatment of chronic hepatitis b (chb) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistična fibroza - drugi proizvodi dihal - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - levkemija, limfocitna, kronična, b-celica - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.